Skip to main content
. 2017 Jun 22;77(12):1369–1376. doi: 10.1007/s40265-017-0782-5

graphic file with name 40265_2017_782_Figa_HTML.jpg

Key milestones in the development of durvalumab. Est estimated completion date, NSCLC non-small cell lung cancer, HNSCC head and neck squamous cell carcinoma, SCLC small cell lung cancer, UC urothelial cancer